^
    Back
    Association details:
    Biomarker:SIRT1 overexpression
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    BMC Cancer
    Title:

    High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma

    Excerpt:
    Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a stepwise decrease of viable cells as depicted in Figure 5. Gefitinib treatment with concentrations of 50 μM showed similar effects as observed for the application of 25 mM nicotinamide.
    DOI:
    10.1186/1471-2407-13-450